Takeda Pharmaceutical CEO Christophe Weber highlighted the importance of gaining a strong foothold in the world’s largest pharma market at…
HOME > REGULATORY
REGULATORY
- Govt’s Draft Reform Timeline Prods MHLW to Discuss Use of “Economic Evaluations” in Reimbursement Decisions in FY2019
December 11, 2018
- Big Improvement in Single-Product, Single-Price Transaction Rate in April-Sept.; Over 90% with Dispensing Pharmacy Chains
December 11, 2018
- Spinraza under PMDA Risk Review for Hydrocephalus
December 10, 2018
- R&D Tax Credit Refit Taking Shape; Open Innovation Scheme Likely to Cover Research Commissioned to Big Firms
December 10, 2018
- Council Holds Off Nonprescription Switches of PPIs Despite Public Support
December 10, 2018
- JPMA Official Renews Call for Use of “Specified Clinical Research” Data in Application Dossiers
December 7, 2018
- Burden on Clinical Research Core Hospitals Should Be Reduced: HSC Panel Chair
December 7, 2018
- National Institute of Public Health to Play Core Role in CEA Public Analysis Process
December 6, 2018
- Chuikyo Agrees on 3 ICER Thresholds for “Tiered” CEA Price Adjustment Model; Industry Hearing Slated by Year-End
December 6, 2018
- Japan Pharma Chief Happy with Direction of Chuikyo Debates on Tax Hike-Linked Price Revision
December 6, 2018
- ViiV’s HIV Drug Juluca to Join NHI Price List on Dec. 12
December 5, 2018
- Survey Suggests 5% Regular Price Cut in 2019, 2% Tax Hike to Offset Reduction
December 5, 2018
- MHLW Panel OKs Amgen Astellas’ Romosozumab, but ADHD Drug Vyvanse Put on Hold
December 4, 2018
- Keytruda’s Tumor-Agnostic Use, Gilead’s Epclusa, Wider Hemlibra Label Now in Line for Approval by Year-End
November 30, 2018
- Govt Deregulation Team Calls for Review of Info Required in Micatrio Reimbursement Claims
November 30, 2018
- LDP Lawmakers Push for Expansion of R&D Tax Credit
November 30, 2018
- AMED Study Group Drafting Japan’s 1st Guidelines for Development of Recombinant Virus Vaccines
November 29, 2018
- MHLW Orders Label Revisions for Mitsubishi Tanabe’s Zione; “Anaphylaxis” to Be Added to Adverse Reactions
November 28, 2018
- Certain Amount of Production Hikes of Measles-Rubella Vaccine in Japan Possible: Health Minister
November 28, 2018
- Pfizer Skips Listing of Herceptin Biosimilar, Daiichi Sankyo Goes Ahead
November 27, 2018
ページ
While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…
Daiichi Sankyo and GlaxoSmithKline recently announced that they have agreed to dissolve their joint venture company, Japan Vaccine. The failure of this model of joint venture between a major Japanese and foreign drug maker in just six years is disappointing.Over…
To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…